Publication Date
1-1-2024
Journal
Therapeutic Advances in Infectious Disease
DOI
10.1177/20499361241241199
PMID
38545450
PMCID
PMC10966995
PubMedCentral® Posted Date
3-26-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Apophysomyces, ibrutinib, invasive fungal infection, mucormycosis
Abstract
The use of ibrutinib, a Bruton tyrosine kinase inhibitor, has been associated with invasive fungal infections (IFIs). We describe a case of Apophysomyces infection associated with long-term use of ibrutinib for the treatment of chronic lymphocytic leukemia as well as perform a literature review of Mucormycosis infections in patients on ibrutinib. Our review found that the onset of IFI can occur within months to years of starting tyrosine kinase inhibitors. These reports provide a more complete picture of the risk of IFI while patients are on ibrutinib. Our case also demonstrates the utility of molecular techniques in the diagnosis of IFI, as the diagnosis was made using 28S rDNA/internal transcribed spacer PCR.
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Biology Commons, Medical Sciences Commons, Medical Specialties Commons